How often will patients need EBGLYSS injections per year after the new approval?

After initial loading doses, patients require one injection every 8 weeks, totaling 6 injections per year.

What is the difference between the old and new dosing schedules?

The old schedule required injections every 4 weeks (13 per year), while the new schedule reduces it to every 8 weeks (6 per year).

Who are the main competitors of EBGLYSS?

Main competitors include Dupixent (Sanofi/Regeneron) and Adbry (Leo Pharma).

Eli Lilly’s EBGLYSS Gets FDA Nod for Every-8-Week Dosing

Eli Lilly (LLY) received FDA approval for an expanded maintenance dosing regimen for EBGLYSS (lebrikizumab-lbkz), allowing injections every eight weeks for patients with moderate-to-severe atopic dermatitis. This reduces the annual number of injections to six.

June 10, 2026

2 min read

Source: Stocktwits

Key Numbers

dosing frequency

every 8 weeks

injections per year

Eli Lilly (LLY) announced that the U.S. Food and Drug Administration (FDA) has approved a new dosing schedule for EBGLYSS (lebrikizumab-lbkz) for the treatment of moderate-to-severe atopic dermatitis. The decision allows maintenance dosing once every eight weeks, cutting the number of annual injections to just six.

The Product

EBGLYSS is a monoclonal antibody that targets IL-13, a key inflammatory pathway in atopic dermatitis. It was initially approved in September 2023 with a loading dose followed by maintenance every four weeks. The new schedule reduces injection frequency by 50%.

Pricing and Availability

Eli Lilly has not announced any change in the drug's price. EBGLYSS is available by prescription and administered via subcutaneous injection.

Competition

EBGLYSS competes with other biologics such as Dupixent (Sanofi/Regeneron) and Adbry (Leo Pharma). The less frequent dosing schedule gives it a competitive advantage in the market.

Potential Impact on the Company

The new dosing regimen is expected to improve patient adherence and expand the user base, potentially boosting EBGLYSS revenues. This is a positive development for Eli Lilly in the dermatology biologics market.

Frequently Asked Questions

EBGLYSS (lebrikizumab-lbkz) is a monoclonal antibody targeting IL-13, used for moderate-to-severe atopic dermatitis.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.